Phase Clinical Study of Surufatinib Combined With Gemcitabine and Cisplatin Plus Durvalumab/Pembrolizumab Regimen in the Treatment of Advanced Biliary Tract Cancer

• Status: RECRUITING
• Trial end date: 2027-07-01

Summary

This phase II trial studies how well gemcitabine, cisplatin and durvalumab/Pembrolizumab and surufatinib work in treating participants with advanced Biliary Tract Cancer. The international multicenter phase III clinical study TOPAZ-1 has confirmed that durvalumab combined with gemcitabine and cisplatin can bring survival benefits to advanced BTC. Whether if adding surufatinib to a standard of care can bring addition benefit needs to be explored.

• Phase: PHASE2

Details

• Lead Sponsor: Dai, Guanghai
• Treatments: Cisplatin; durvalumab; Gemcitabine; pembrolizumab; surufatinib